Cargando…

Doxorubicin Hydrochloride-Loaded Nonionic Surfactant Vesicles to Treat Metastatic and Non-Metastatic Breast Cancer

[Image: see text] Doxorubicin hydrochloride (DOX) is currently used to treat orthotropic and metastatic breast cancer. Because of its side effects, the use of DOX in cancer patients is sometimes limited; for this reason, several scientists tried designing drug delivery systems which can improve drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Francesco, Martina, Celia, Christian, Cristiano, Maria Chiara, d’Avanzo, Nicola, Ruozi, Barbara, Mircioiu, Constantin, Cosco, Donato, Di Marzio, Luisa, Fresta, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860091/
https://www.ncbi.nlm.nih.gov/pubmed/33553916
http://dx.doi.org/10.1021/acsomega.0c05350
_version_ 1783646871052353536
author Di Francesco, Martina
Celia, Christian
Cristiano, Maria Chiara
d’Avanzo, Nicola
Ruozi, Barbara
Mircioiu, Constantin
Cosco, Donato
Di Marzio, Luisa
Fresta, Massimo
author_facet Di Francesco, Martina
Celia, Christian
Cristiano, Maria Chiara
d’Avanzo, Nicola
Ruozi, Barbara
Mircioiu, Constantin
Cosco, Donato
Di Marzio, Luisa
Fresta, Massimo
author_sort Di Francesco, Martina
collection PubMed
description [Image: see text] Doxorubicin hydrochloride (DOX) is currently used to treat orthotropic and metastatic breast cancer. Because of its side effects, the use of DOX in cancer patients is sometimes limited; for this reason, several scientists tried designing drug delivery systems which can improve drug therapeutic efficacy and decrease its side effects. In this study, we designed, prepared, and physiochemically characterized nonionic surfactant vesicles (NSVs) which are obtained by self-assembling different combinations of hydrophilic (Tween 20) and hydrophobic (Span 20) surfactants, with cholesterol. DOX was loaded in NSVs using a passive and pH gradient remote loading procedure, which increased drug loading from ∼1 to ∼45%. NSVs were analyzed in terms of size, shape, size distribution, zeta potential, long-term stability, entrapment efficiency, and release kinetics, and nanocarriers having the best physiochemical parameters were selected for further in vitro tests. NSVs with and without DOX were stable and showed a sustained drug release up to 72 h. In vitro studies, with MCF-7 and MDA MB 468 cells, demonstrated that NSVs, containing Span 20, were better internalized in MCF-7 and MDA MB 468 cells than NSVs with Tween 20. NSVs increased the anticancer effect of DOX in MCF-7 and MDA MB 468 cells, and this effect is time and dose dependent. In vitro studies using metastatic and nonmetastatic breast cancer cells also demonstrated that NSVs, containing Span 20, had higher cytotoxicity than NSVs with Tween 20. The resulting data suggested that DOX-loaded NSVs could be a promising nanocarrier for the potential treatment of metastatic breast cancer.
format Online
Article
Text
id pubmed-7860091
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-78600912021-02-05 Doxorubicin Hydrochloride-Loaded Nonionic Surfactant Vesicles to Treat Metastatic and Non-Metastatic Breast Cancer Di Francesco, Martina Celia, Christian Cristiano, Maria Chiara d’Avanzo, Nicola Ruozi, Barbara Mircioiu, Constantin Cosco, Donato Di Marzio, Luisa Fresta, Massimo ACS Omega [Image: see text] Doxorubicin hydrochloride (DOX) is currently used to treat orthotropic and metastatic breast cancer. Because of its side effects, the use of DOX in cancer patients is sometimes limited; for this reason, several scientists tried designing drug delivery systems which can improve drug therapeutic efficacy and decrease its side effects. In this study, we designed, prepared, and physiochemically characterized nonionic surfactant vesicles (NSVs) which are obtained by self-assembling different combinations of hydrophilic (Tween 20) and hydrophobic (Span 20) surfactants, with cholesterol. DOX was loaded in NSVs using a passive and pH gradient remote loading procedure, which increased drug loading from ∼1 to ∼45%. NSVs were analyzed in terms of size, shape, size distribution, zeta potential, long-term stability, entrapment efficiency, and release kinetics, and nanocarriers having the best physiochemical parameters were selected for further in vitro tests. NSVs with and without DOX were stable and showed a sustained drug release up to 72 h. In vitro studies, with MCF-7 and MDA MB 468 cells, demonstrated that NSVs, containing Span 20, were better internalized in MCF-7 and MDA MB 468 cells than NSVs with Tween 20. NSVs increased the anticancer effect of DOX in MCF-7 and MDA MB 468 cells, and this effect is time and dose dependent. In vitro studies using metastatic and nonmetastatic breast cancer cells also demonstrated that NSVs, containing Span 20, had higher cytotoxicity than NSVs with Tween 20. The resulting data suggested that DOX-loaded NSVs could be a promising nanocarrier for the potential treatment of metastatic breast cancer. American Chemical Society 2021-01-22 /pmc/articles/PMC7860091/ /pubmed/33553916 http://dx.doi.org/10.1021/acsomega.0c05350 Text en © 2021 The Authors. Published by American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.
spellingShingle Di Francesco, Martina
Celia, Christian
Cristiano, Maria Chiara
d’Avanzo, Nicola
Ruozi, Barbara
Mircioiu, Constantin
Cosco, Donato
Di Marzio, Luisa
Fresta, Massimo
Doxorubicin Hydrochloride-Loaded Nonionic Surfactant Vesicles to Treat Metastatic and Non-Metastatic Breast Cancer
title Doxorubicin Hydrochloride-Loaded Nonionic Surfactant Vesicles to Treat Metastatic and Non-Metastatic Breast Cancer
title_full Doxorubicin Hydrochloride-Loaded Nonionic Surfactant Vesicles to Treat Metastatic and Non-Metastatic Breast Cancer
title_fullStr Doxorubicin Hydrochloride-Loaded Nonionic Surfactant Vesicles to Treat Metastatic and Non-Metastatic Breast Cancer
title_full_unstemmed Doxorubicin Hydrochloride-Loaded Nonionic Surfactant Vesicles to Treat Metastatic and Non-Metastatic Breast Cancer
title_short Doxorubicin Hydrochloride-Loaded Nonionic Surfactant Vesicles to Treat Metastatic and Non-Metastatic Breast Cancer
title_sort doxorubicin hydrochloride-loaded nonionic surfactant vesicles to treat metastatic and non-metastatic breast cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860091/
https://www.ncbi.nlm.nih.gov/pubmed/33553916
http://dx.doi.org/10.1021/acsomega.0c05350
work_keys_str_mv AT difrancescomartina doxorubicinhydrochlorideloadednonionicsurfactantvesiclestotreatmetastaticandnonmetastaticbreastcancer
AT celiachristian doxorubicinhydrochlorideloadednonionicsurfactantvesiclestotreatmetastaticandnonmetastaticbreastcancer
AT cristianomariachiara doxorubicinhydrochlorideloadednonionicsurfactantvesiclestotreatmetastaticandnonmetastaticbreastcancer
AT davanzonicola doxorubicinhydrochlorideloadednonionicsurfactantvesiclestotreatmetastaticandnonmetastaticbreastcancer
AT ruozibarbara doxorubicinhydrochlorideloadednonionicsurfactantvesiclestotreatmetastaticandnonmetastaticbreastcancer
AT mircioiuconstantin doxorubicinhydrochlorideloadednonionicsurfactantvesiclestotreatmetastaticandnonmetastaticbreastcancer
AT coscodonato doxorubicinhydrochlorideloadednonionicsurfactantvesiclestotreatmetastaticandnonmetastaticbreastcancer
AT dimarzioluisa doxorubicinhydrochlorideloadednonionicsurfactantvesiclestotreatmetastaticandnonmetastaticbreastcancer
AT frestamassimo doxorubicinhydrochlorideloadednonionicsurfactantvesiclestotreatmetastaticandnonmetastaticbreastcancer